Cost-Effectiveness Analysis of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis
10.3870/j.issn.1004-0781.2025.06.019
- VernacularTitle:氘可来昔替尼治疗中重度斑块状银屑病的成本-效果分析
- Author:
Bing FENG
1
;
Ning GAO
;
Shengnan GAO
;
Ranran ZHANG
;
Yuxi ZHANG
;
Guoqiang LIU
Author Information
1. 河北医科大学第三医院临床药学部,石家庄 050051
- Publication Type:Journal Article
- Keywords:
Deucravacitinib;
Psoriasis;
Pharmacoeconomics;
Health technologyassessment
- From:
Herald of Medicine
2025;44(6):955-960
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of deucravacitinib in the treatment of moderate to severe plaque psoriasis from the perspective of the Chinese health system.Methods Based on POETYK PSO-1 study and related cost and utility data,a decision tree combined with Markov model was established.The model period was 10 years,and the output indicators of the model were cost and quality-adjusted life year(QALY).The evaluation index of the model was the incremental cost-effectiveness ratio(ICER).The willingness-to-pay threshold(WTP)was 3 times of China's per capita GDP in 2023.Sensitivity analysis was performed to evaluate the robustness of the model results.Results The incremental utility and incremental cost were 0.598QALYs and 130 677.51 yuan(RMB),respectively.The ICER of the two strategies was 218 487.11 yuan(RMB)per QALY gained,which was less than 3 times GDP per capita in 2023.Sensitivity analyses confirmed the robustness of the model.Conclusion Under the threshold of 3 times the GDP per capita in China,deucravacitinib is cost-effective in the treatment of moderate to severe plaque psoriasis.
